| Old Articles: <Older 7421-7430 Newer> |
|---|
 |
The Motley Fool
May 10, 2011
Brian Orelli |
Waiting for MannKind's Pot of Gold It's going to be awhile.   |
The Motley Fool
May 10, 2011
Brian Orelli |
Uncontrolled Crying Over AVANIR's Prescription Data? It's been a slow start, but don't write off this company's pseudobulbar drug just yet. |
The Motley Fool
May 10, 2011
Brian Orelli |
Pfizer's Multibillion-Dollar Blockbuster Set to Grow Pfizer will make money off old people, too. |
The Motley Fool
May 10, 2011
Frank Vinluan |
Salix Sued by Partner for "Breach" Over HIV-Associated Drug Who will take this blockbuster drug to market? |
The Motley Fool
May 10, 2011
Arundhati Parmar |
Medtronic's MR-Conditional Pacemaker Likely Too Expensive Is Medtronic's pricing choice dragging on this breakthrough product? |
The Motley Fool
May 9, 2011
Brian Orelli |
Why Is Sequenom Up 20%? Investors appear to be overreacting. |
Chemistry World
May 9, 2011
Andrew Turley |
New data reignites eye drug debate Interim results from a much anticipated comparative study of two drugs support what many ophthalmologists already believe: that ranibizumab and bevacizumab are equally good for the treatment of neovascular age related macular degeneration. |
The Motley Fool
May 9, 2011
Brian Orelli |
In Biotech, Two Platforms Are Better Than One Alkermes has swooped in and agreed to buy Elan Drug Technology for around $960 million. |
The Motley Fool
May 4, 2011
Brian Orelli |
For Pfizer, Breaking Up Is Hard to Do CEO Ian Read pushes back the decision on the company's breakup until 2012. |
The Motley Fool
May 4, 2011
Brian Orelli |
Cell Therapeutics: Denied but Not Rejected Cell Therapeutics' ball may be headed for the end zone, but the FDA has an eight-foot free safety ready to bat it down. |
| <Older 7421-7430 Newer> Return to current articles. |
